<unk>  (INNs) is a combination drug for the treatment of HIV infection. It is marketed as Kivexa in most countries except for the United States, where it is branded as Epzicom. It is a fixed dose combination of<unk>  (3TC, Epivir) and<unk>   (ABC, Ziagen).<unk>  and<unk>  are both nucleoside reverse transcriptase inhibitors (NRTI).
It was approved by the FDA on August 2, 2004. It is marketed by ViiV Healthcare.
Abacavir lamivudine
Fosamprenavir
Emtricitabine rilpivirine tenofovir
Ledipasvir / sofosbuvir
Lopinavir ritonavir
Sofosbuvir / velpatasvir
Saquinavir
Dolutegravir / rilpivirine